## MANAGEMENT'S DISCUSSION AND ANALYSIS

FOR THE THREE MONTHS ENDED MARCH 31, 2020 AND 2019

### MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS FOR THE THREE MONTHS ENDED MARCH 31, 2020 AND 2019

This management discussion and analysis ("MD&A") of the financial condition and results of operations of Indus Holdings, Inc. (the "Company", "we", "our", "us" or "Indus"), formerly known as Mezzotin Minerals Inc., is for the three months ended March 31, 2020 and 2019. It is supplemental to, and should be read in conjunction with, the Company's consolidated financial statements and the accompanying notes for the three months ended March 31, 2020 and 2019. The Company's financial statements are prepared in accordance with International Financial Reporting Standards ("IFRS"). All amounts in this MD&A are expressed in thousands of United States dollars ("\$" or "US\$"), unless otherwise indicated.

*This MD&A has been prepared by reference to the MD&A disclosure requirements established under National Instrument* 51-102 – Continuous Disclosure Obligations of the Canadian Securities Administrators.

This MD&A contains certain "forward-looking statements" and "forward-looking information" as defined under applicable Canadian and United States securities laws. Please refer to the discussion of forward-looking statements and information set out under the heading "Cautionary Note Regarding Forward-Looking Information", located at the beginning of the Company's Listing Statement filed on SEDAR. As a result of many factors, the Company's actual results may differ materially from those anticipated in these forward-looking statements and information.

#### Non-IFRS Financial Measures

The Company has provided certain supplemental non-IFRS financial measures in this MD&A. Where the Company has provided such non-IFRS financial measures, we have also provided a reconciliation to the most comparable IFRS financial measure. These supplemental non-IFRS financial measures should not be considered superior to, as a substitute for or as an alternative to, and should only be considered in conjunction with, the IFRS financial measures presented herein.

In this MD&A, reference is made to gross profit before fair value adjustments or adjusted gross profit (loss), adjusted gross margin, adjusted EBITDA, and working capital which are not measures of financial performance under IFRS. The Company calculates each as follows:

- Gross profit (loss) before fair value adjustments (adjusted gross profit) is equal to gross profit less the non-cash increase (plus the non-cash decrease) in the fair value adjustments on sale of inventory and on growth of biological assets, if any. Management believes this measure provides useful information as it removes fair value metrics tied to increasing stock levels (decreasing stock levels) required by IFRS.
- Adjusted gross margin is gross profit (loss) before fair value adjustments divided by net revenue. Management believes this measure provides useful information as it represents the gross profit (loss) based on the Company's cost to produce inventory sold and removes fair value metrics tied to increasing stock levels (decreasing stock levels) required by IFRS.
- Adjusted EBITDA is net income (loss), excluding the effects of income taxes (recovery); net interest expense; depreciation and amortization; non-cash fair value adjustments on investments; unrealized foreign currency gains/losses; non-cash fair value adjustments on sale of inventory and on growth of biological assets; share-

## MANAGEMENT'S DISCUSSION AND ANALYSIS

### FOR THE THREE MONTHS ENDED MARCH 31, 2020 AND 2019

based compensation expense; and other transactional and special expenses, such as acquisition costs and expenses related to our reverse takeover, which are inconsistent in amount and frequency and are not what we consider as typical of our continuing operations. Management believes this measure provides useful information as it is a commonly used measure in the capital markets and as it is a close proxy for repeatable cash generated by operations.

Working capital is current assets less current liabilities. Management believes the calculation of working capital provides additional information to investors about the Company's liquidity.

These measures are not necessarily comparable to similarly titled measures used by other companies.

Neither the Canadian Securities Exchange nor its Regulation Service Provider has reviewed and does not accept responsibility for the adequacy or accuracy of the content of this MD&A.

This MD&A is prepared as of May 28, 2020.

#### 1. OVERVIEW OF THE COMPANY

Indus is a California-based cannabis company with vertically integrated operations including large scale cultivation, extraction, processing, manufacturing, branding, packaging and wholesale distribution to licensed retail dispensaries statewide. Indus offers services supporting every step of the supply chain from seed to sale and an extensive portfolio of award-winning brands, including owned brands, such as Cypress Cannabis, House Weed, Kaizen Medicinals, Altai, Acme, and Moon, and agency brands, such as Dixie, Purity, Dr. Raw and Kin Slips.

The Company was founded by Robert Weakley who has played a pioneering role in the emergence of the regulated cannabis market in California. Together with co-founder Mark Ainsworth and the Indus team, the vision for Indus was introduced to the industry in 2014 with the development of Altai as its first brand of edibles. The Company leverages technology, innovation, product quality and superior service levels to continuously develop its customer and partner networks of top-tier industry retailers and innovators. Our strategy focuses on four core pillars: the quality of our products, brand awareness, distribution capabilities, and utilization of existing capacity. Indus is backed by an experienced team that is deeply in tune and integrated with industry partners and the Company's customers. Together, we are building a new American Industry, creating products that emphasize consumer safety while advancing changing perceptions of cannabis use.

The Company operates a 225,000 square foot cultivation facility in Monterey County and a manufacturing and laboratory facility in Salinas, California for production of extracts, distillates and branded and packaged cannabis flower, concentrates and edible products. The Company also distributes proprietary and third-party brands throughout the State of California and maintains warehouses and distribution vehicles in Central and Southern California.

In addition to owning cultivation, manufacturing and distribution cannabis licenses and operations, the Company also provides manufacturing, extraction and distribution services to third-party cannabis manufacturers and cannabis branding companies. Presently the Company also directs and funds operations in Nevada and Oregon, which will become Indus operations upon license transfer in those states as discussed in Note 4 of the Company's condensed interim consolidated financial statements.

## MANAGEMENT'S DISCUSSION AND ANALYSIS

FOR THE THREE MONTHS ENDED MARCH 31, 2020 AND 2019

Indus' operations are comprised of the following companies:

- Indus Holding Company, wholly owned by Indus Holdings, Inc.
- Cypress Holding Company, wholly owned by Indus Holding Company
- Cypress Manufacturing Company, wholly owned by Indus Holding Company
- Indus Nevada LLC, wholly owned by Indus Holding Company
- Indus Oregon LLC, wholly owned by Indus Holding Company
- Indus Brand Management LLC, wholly owned by Indus Holding Company
- Wellness Innovation Group LLC, wholly owned by Indus Holding Company

The Company's corporate office and principal place of business is located at 19 Quail Run Circle, Salinas, California. As of March 31, 2020, the Company had 269 fulltime-equivalent employees.

#### **Reverse Takeover**

On November 13, 2018, Indus Holding Company (a wholly owned subsidiary of Indus Holdings, Inc.) and Mezzotin Minerals Inc. ("Mezzotin") entered into a combination agreement whereby the parties agreed to combine their respective businesses, which would result in the reverse takeover of Mezzotin by the security holders of Indus. Mezzotin Minerals was originally incorporated under the Business Corporations Act (Ontario) on October 27, 2005 as Zoolander Corporation. On September 10, 2013, Zoolander changed its name to Mezzotin Minerals Inc. On April 26, 2019 the reverse takeover transaction concluded. In connection with the agreement, Mezzotin changed its name from Mezzotin Minerals Inc. to Indus Holdings, Inc. (the "Company", "Pubco", or "Indus"). Effective at the close of markets on April 29, 2019, the common shares of the Company ("Existing Mezzotin Shares") were delisted from the NEX board of the TSX Venture Exchange, and the subordinate voting shares of the Company commenced trading on the Canadian Stock Exchange effective at market open on April 30, 2019, under the new symbol "INDS".

Indus Holding Company ("IHC"), a Delaware corporation, was formed in 2014. Indus Holdings, Inc. became the indirect parent of IHC in connection with the reverse takeover transaction. The comparative amounts presented for the three months ended March 31, 2019 are those of IHC.

#### **Recent Developments**

#### Financing

On April 13, 2020, the Company announced that its subsidiary, Indus Holding Company, entered into a \$15.1 million senior secured convertible debenture and warrant purchase agreement. In May 2020 an additional \$1 million was funded to bring the total convertible debenture amount to \$16.1 million. The convertible debentures are convertible, at a conversion price of \$0.20 per share, into an aggregate of 80.4 million subordinate voting shares of the Company, and the Company issued warrants to purchase an aggregate of 80.4 million subordinate voting shares at an exercise price of \$.28 per share. The financing yielded the Company approximately \$11.5 million after repayment of \$3.8 million in bridge financing received during the first quarter, plus accrued interest thereon, and transaction related expenses of approximately \$600. The debentures bear interest at 5.5% per annum and will mature in October 2023, and the warrants also mature in October 2023.

# INDUS HOLDINGS, INC. AND AFFILIATES MANAGEMENT'S DISCUSSION AND ANALYSIS

### FOR THE THREE MONTHS ENDED MARCH 31, 2020 AND 2019

#### Acquisitions

On April 18, 2019, the Company acquired all of the assets, global rights and business interests associated with the brand Humble Flower Co. for a purchase price of \$472 that will be paid as and if financial performance targets are met during the period beginning on April 19, 2019 and ending on April 18, 2023. The acquisition marks the Company's expansion into cannabis-infused topical creams, balms, and oils.

On May 1, 2019, the Company acquired all of the assets, global rights and business interests of Kaizen Inc. for a purchase price of \$556 that will be paid as and if financial performance targets are met during the period beginning on May 1, 2019 and ending on April 30, 2023. Kaizen is a premium brand offering a full spectrum of cannabis concentrates.

On May 14, 2019, the Company entered into a definitive agreement to acquire the assets of W The Brand ("W Vapes"), a multi-state manufacturer and distributor of cannabis concentrates, cartridges and disposable pens, in a cash and stock transaction. When completed, the acquisition will enable Indus to expand our brand offerings to new customers in Nevada and Oregon. Under the terms of the agreement, the purchase consideration to W Vapes shareholders consists of \$10 million in cash and \$10 million in shares of Indus Holdings, Inc. common equity (based on a deemed value of CDN\$15.65 per share). The transaction includes the operating assets; all intellectual property; and cultivation, manufacturing, and distribution licenses and operations in Las Vegas, Nevada and Portland, Oregon. In connection with the transaction, Indus and W Vapes have entered into a management services agreement that terminates upon completion of the acquisition. In November 2019, the definitive agreement was amended whereby the Company advanced \$2 million in non-recourse funds to the seller in exchange for release of \$10 million of cash held in escrow related to the acquisition. Additionally, in December 2019, the Company purchased the Las Vegas, Nevada facility for \$4.1 million. The completion of the acquisition is subject to regulatory approvals including the successful transfer of the Nevada and Oregon cannabis licenses to Indus.

On June 12, 2019, the Company completed the acquisition of 70% of the outstanding capital stock of Shredibles LLC, a manufacturer of CBD infused health products. The Company transferred an aggregate consideration of \$240 comprised of 42.6 thousand subordinate voting shares with an acquisition-date fair value of \$5.64 per share. The acquisition is a strategic investment that expands the Company's brand portfolio into the CBD protein bar market and provides development opportunities for products with crossover offerings in CBD and THC versions. In February 2020, the Company determined that Shredibles was not a strategic fit for the Company at this time and reached an agreement with the Shredibles co-founders to nullify the investment and the investment consideration of 42.6 thousand subordinate voting shares were returned to the Company. The termination has been reflected as being effective as of December 31, 2019 in the consolidated financial statements. The operations of Shredibles, and the termination of the agreement, did not have a material impact on the results of operations of the Company in 2019

On September 17, 2019, the Company announced that the OTC Markets Group, Inc. approved the trading of Indus Holdings, Inc. shares on the OTCQX<sup>®</sup> Best Market, the premium market tier of OTC Markets Group. Shares commenced trading at the opening of the market on September 17, 2019 under the symbol "INDXF."

In recognition of its ongoing commitment to Monterey County and its contributions to the Northern California economy, Indus was awarded Monterey County Business Council's 2019 Agriculture Award.

# INDUS HOLDINGS, INC. AND AFFILIATES MANAGEMENT'S DISCUSSION AND ANALYSIS

FOR THE THREE MONTHS ENDED MARCH 31, 2020 AND 2019

#### Management Changes

Effective April 13, 2020, Mark Ainsworth, Co-Founder, has been appointed to the role of Interim Chief Executive Officer following Robert Weakley's resignation from the Company. Mark has been instrumental to Indus' vision and growth strategy since inception and will focus on successfully executing the company's strategic plans to get the Company to profitability. Robert Weakley will remain on the Board of Directors. Additionally, Steve Neil has been appointed Chief Financial Officer, which follows Tina Maloney's retirement in December 2019, and Kelly Crampton has been appointed Senior Vice President of Distribution.

#### **Operations and Regulatory Overview**

We believe Indus' operations are in full compliance with all applicable state and local laws, regulations and licensing requirements in the states in which we operate. Substantially all our revenue is derived from the U.S. cannabis industry, which is illegal under U.S. federal law. For a regulatory overview of the states in which we operate and information about risks related to U.S. cannabis operations, please refer to the Company's Listing Statement filed under the Company's profile on SEDAR.

#### **Reconciliations of Non-IFRS Financial and Performance Measures**

The table below reconciles Net Loss to Adjusted EBITDA for the periods indicated.

	Three Mo	nths Ended
	Mar	ch 31,
(in thousands)	2020	2019
Net loss attributable to Indus Holdings, Inc. (IFRS)	\$ (4,125)	\$ (4,934)
Interest expense	850	783
Provision (benefit) for income taxes	25	-
Depreciation in cost of goods sold	86	147
Depreciation and amortization in operating expenses	877	695
Investment and currency gains	(85)	-
Share-based compensation	1,612	131
Net effect of change in fair value of biological assets	(3,696)	645
Adjusted EBITDA (non-IFRS)	\$ (4,455)	\$ (2,533)
(1) Non JEPS magging		

Non-IFRS measure

## MANAGEMENT'S DISCUSSION AND ANALYSIS

### FOR THE THREE MONTHS ENDED MARCH 31, 2020 AND 2019

The table below reconciles Gross Profit (Loss) and Gross Margin to Adjusted Gross Profit (Loss) and Adjusted Gross Margin for the periods indicated.

#### Three Months Ended March 31,

2020		2019
\$ 9,442	\$	6,434
\$ 10,604	\$	5,086
\$ (3,696)	\$	645
\$ 2,534	\$	703
\$ (1,162)	\$	1,348
-12.3%		21.0%
	\$ 10,604 \$ (3,696) \$ 2,534 \$ (1,162)	\$ 10,604 \$ \$ (3,696) \$ \$ 2,534 \$ \$ (1,162) \$

<sup>(1)</sup> Non-IFRS measure

#### 2. SELECTED FINANCIAL DATA

The following table presents selected financial data derived from the consolidated financial statements of the Company as at and for the three months ended March 31, 2020 and 2019. The selected consolidated financial information set out below may not be indicative of the Company's future performance.

(in thousands, except per share amounts)	2020	2019
		2015
Statement of Operations Data:		
Net revenue	\$ 9,442	\$ 6,434
Cost of goods sold	\$ 10,604	\$    5,086
Net effect of change in fair value of biological assets	\$ (3,696)	\$ 645
Gross profit	\$ 2,534	\$ 703
Adjusted gross profit (loss) <sup>(1)</sup>	\$ (1,162)	\$ 1,348
Adjusted gross margin <sup>(1)</sup>	-12.3%	21.0%
Total operating expenses	\$ 5,894	\$ 4,461
Total other income/(expense)	\$ (740)	\$ (1,176)
Benefit (provision) for income taxes	\$ (25)	\$ -
Net loss	\$ (4,125)	\$ (4,934)
Per Share Data:		
Net loss attributable to Indus Holdings Inc. per share:		
Basic	\$ (0.13)	
Diluted	\$ (0.13)	
Shares used in per share calculation:		
Basic	32,988	
Adjusted EBITDA <sup>(1)</sup>	\$ (4,455)	\$ (2,533)

(1) Non-IFRS measure

## MANAGEMENT'S DISCUSSION AND ANALYSIS

### FOR THE THREE MONTHS ENDED MARCH 31, 2020 AND 2019

(in thousands) Balance Sheet Data:		March 31, 2020	December 31, 2019		
Cash and cash equivalents	\$	587	\$	1,344	
Working capital	\$	9,927	\$	10,004	
Total assets	\$	70,636	\$	69,208	
Long-term notes payable including current portion	\$	3,758	\$	506	
Capital lease obligations including current portion	\$	33,424	\$	33,805	
Total liabilities	\$	48,789	\$	44,848	
Total shareholders' equity	\$	21,847	\$	24,360	

#### Three Months Ended March 31, 2020 Compared to Three Months Ended March 31, 2019

#### Revenue

We derive our revenue from sales of extracts, distillates, branded and packaged cannabis flower, concentrates and edible products to retail dispensaries in the state of California. In addition, we distribute proprietary and third-party brands throughout the state of California. The Company recognizes revenue upon delivery of goods to customers since at this time performance obligations are satisfied.

The Company classifies its revenues into three major categories: Owned, Agency and Distributed brands.


- Owned are the proprietary brands of the Company.
- Agency brands are third-party brands that the Company manufactures and/or sells utilizing our in-house sales team and distributes on behalf of the third-party.
- Distributed brands are brands in which the Company provides distribution services to retail dispensaries. Distributed brands also include third-party sourced bulk product sales.

## MANAGEMENT'S DISCUSSION AND ANALYSIS

FOR THE THREE MONTHS ENDED MARCH 31, 2020 AND 2019

Revenue by Category

### **Revenue by Category**



Three Months Ended March 31,			2020 v 2019
(in thousands)	2020	 2019	% Change
Owned	\$ 5,207	\$ 2,211	135%
Agency	2,709	2,123	28%
Distributed	1,526	2,099	-27%
Net revenue	\$ 9,442	\$ 6,434	47%

In the three months ended March 31, 2020:

• Revenue increases compared to the prior year were driven by continued customer onboarding, expansion of product offerings, sales from acquired brands and targeted marketing initiatives.

Indus expects to focus on profitable sales growth in 2020 primarily through expanded cultivation capacity in the second half of the year. Flower capacity in 2020 is expected to increase almost three times over 2019 to 25,000 – 27,500 pounds harvested, which will also increase internally sourced materials for extraction and concentrate products. The increased flower output, which is expected to start to harvest late in the second quarter, will enable multiple strains to be available at all times for our retail partners and will facilitate SKU expansion into existing and newly opened dispensaries. Revenues are also expected to increase, although at a lesser pace, through improved penetration of edible products and selective new product introductions. Our focus on agency and distributed brand sales will be on those brands that realize a higher per order sales level that will enable profitable growth.

#### Cost of Sales, Gross Profit and Gross Margin

Cost of goods sold currently consist of the following categories:

 Product Costs – Includes all direct and indirect costs of production and distribution, and includes amounts paid for direct labor, raw materials, packaging, operating supplies, and allocated overhead, which includes allocations of rent, insurance, managerial salaries, utilities, and other expenses, such as employee training and product testing. Our focus in 2020 is on flower, pre-rolls, concentrates and vertical integration which will

## MANAGEMENT'S DISCUSSION AND ANALYSIS

### FOR THE THREE MONTHS ENDED MARCH 31, 2020 AND 2019

enable us to achieve profitability resulting from our expanded cultivation operations in the second half of the year.

- Agency brand manufacturing The Company manufactures products for certain brands that do not have the capability, licensing or capacity to manufacture their own products. The fees earned for these activities absorbs fixed overhead in manufacturing. In 2020, the Company is focusing on reducing its focus on agency brand manufacturing while focusing on smaller, more frequent production runs to lower inventory working capital, optimize efficiencies and expedite product getting to the market faster.
- Net Effect of the Change in Fair Value of Biological Assets These fair value adjustments are part of the Company's cost of sales as required in accordance with IFRS standards relating to agriculture and biological assets. The fair value adjustment on sale of inventory represents the effect of the non-cash fair value adjustment on inventory sold in the period.

Management believes that the use of non-cash IFRS adjustments in calculating gross profit and gross margin can be confusing due to the potentially large value of non-cash fair value metrics required. Accordingly, management believes the use of gross profit (loss) before fair value adjustments and adjusted gross margin provides a better representation of performance by excluding non-cash fair value metrics required by IFRS.

(in thousands, except per share amounts)	2020	2019
Net revenue	\$ 9,442	\$ 6,434
Cost of goods sold	\$ 10,604	\$ 5,086
Net effect of change in fair value of biological assets	\$ (3,696)	\$ 645
Gross profit	\$ 2,534	\$ 703
Adjusted gross profit (loss) <sup>(1)</sup>	\$ (1,162)	\$ 1,348
Adjusted gross margin <sup>(1)</sup>	-12.3%	21.0%

<sup>(1)</sup> Non-IFRS measure

Gross margin was 26.8% and 10.9% in the three months ended March 31, 2020 and 2019, respectively. Excluding the net effect of change in fair value of biological assets, the corresponding gross margins were (12.3)% and 21.0% for the three months ended March 31, 2020 and 2019, respectively. The increase between periods in gross profit and gross margin, as reported, is primarily due to the favorable impact of the net effect of the change in fair value of biological assets. Excluding this effect, gross profit and gross margin declined in the most recent period, primarily due to fully burdening distribution operations, higher pricing discounts and cannabis taxes, and costs of servicing Nevada and Oregon operations. Gross margins are expected to significantly improve and be positive in the second half of the year as cultivation output and operating volumes increase.

#### Total Operating Expenses

Total operating expenses consist primarily of costs incurred at our corporate offices; personnel costs; selling, marketing, and other professional service costs including legal and accounting; and licensing costs. Sales and marketing expenses consist of selling costs to support our customer relationships, including investments in marketing and brand activities and corporate infrastructure required to support our ongoing business. We expect selling costs as a percentage of revenue to decrease as our business continues to grow, due to efficiencies associated with scaling the business, restructuring of commission plans and reduced focus on non-core brands. We expect to incur periodic acquisition and

## MANAGEMENT'S DISCUSSION AND ANALYSIS

### FOR THE THREE MONTHS ENDED MARCH 31, 2020 AND 2019

transaction costs related to expansion efforts and to continue to invest where appropriate in the general and administrative function to support the increasing complexity of the cannabis business.

#### Three Months Ended March 31,

(in thousands)	2020	2019
Total operating expenses	\$ 5,894	\$ 4,461

Total operating expenses increased by \$1,433, or 32% for the three months ended March 31, 2020 compared to the same period in the prior year, attributable to an increase in stock based compensation expense of \$1,481 between periods. Stock based compensation expense is expect to decrease significantly for the balance of 2020 as restricted stock unit grants associated with the reverse takeover fully vested at the end of the first quarter. Sales and marketing expenses declined \$220 from the corresponding period in the prior year, and were 13% of sales compared to 23% in the prior year. The decline between years was due to a reduction in compensation and product marketing expenses. General and administrative expenses, excluding stock compensation expense, increased \$10 in the three months ended March 31, 2020 compared to the same period in the prior year, and was 23% of sales compared to 34% in the prior year. The decline as a percentage of sales was due to lower compensation expense and fully burdening cost of goods sold with distribution-related expenses.

#### Total other income (expense), net

Three Months Ended March 31,			
(in thousands)	2	2020	2019
Total other income/(expense)	\$	(740)	\$ (1,176)

The decrease of other expense in the three months ended March 31, 2020 compared to the corresponding period in 2019 was primarily driven by non-operating expenses incurred in 2019. Interest expense in the three months ended March 31, 2020 increased \$67 from the same period in 2019 due to bridge financing entered into in the quarter.

Net Loss

### Three Months Ended March 31,

(in thousands)	2020	2019
Net loss	\$ (4,125)	\$ (4,934)
Net loss per share:		
Basic	\$ (0.13)	
Diluted	\$ (0.13)	
Shares used in per share calculation:		
Basic	32,988	
Diluted	32,988	

The increase in net loss was driven by the factors described above.

## MANAGEMENT'S DISCUSSION AND ANALYSIS

### FOR THE THREE MONTHS ENDED MARCH 31, 2020 AND 2019

#### Summary of Quarterly Results

The table below presents selected financial information for each of the eight most recently completed quarters

		Net	
Three Months Ended	R	evenue	Net Loss
March 31, 2020	\$	9,442	\$ (4,125)
December 31, 2019	\$	10,803	\$ (18,338)
September 30, 2019	\$	10,119	\$ (19,638)
June 30, 2019	\$	9,689	\$ (7,841)
March 31, 2019	\$	6,434	\$ (4,934)
December 31, 2018	\$	6,259	\$ (3,546)
September 30, 2018	\$	5,217	\$ (849)
June 30, 2018	\$	3,423	\$ (2,115)

#### 3. LIQUIDITY AND CAPITAL RESOURCES

Our primary need for liquidity is to fund the working capital requirements of our business, capital expenditures, general corporate purposes, and to a lesser extent debt service. Our primary source of liquidity is funds generated by financing activities. Our ability to fund our operations, to make planned capital expenditures, to make scheduled debt payments and to repay or refinance indebtedness depends on our future operating performance and cash flows, and ability to obtain equity or debt financing, which are subject to prevailing economic conditions, as well as financial, business and other factors, some of which are beyond our control. Cash generated from ongoing operations in 2019 and in the three months ended March 31, 2020 were not sufficient to fund operations and, in particular, to fund the Company's cultivation capital expenditures in the short-term, and growth initiatives in the long-term. The Company raised additional funds from a \$16.1 million convertible debt financing which was completed in April 2020.

As of March 31, 2020, the Company had \$587 of cash and cash equivalents, and \$9.9 million of working capital, compared to \$1.3 million of cash and cash equivalents and \$10.0 million of working capital as of December 31, 2019.

The Company is focused on improving its balance sheet by improving accounts receivable collections, right-sizing inventories and reducing operating costs. We have taken a number of steps to improve our cash position and to continue to fund operations and capital expenditures including:

- Entered into a \$16.1 million senior secured convertible debenture and warrant purchase agreement in April 2020. The debentures bear interest at 5.5% per annum and will mature in October 2023. See Note 22 in the condensed interim consolidated financial statements.
- Accelerate cultivation facility renovations which are expected to result in an increase in flower and trim output by approximately 2.5 times in 2020, and over 4 times on an annualized basis compared to 2019.
- Terminated the technology agreement with our e-commerce partner to reduce distribution expenses.
- Scaled back our investment in and support for non-core brands.
- Restructured our organization and identified operating, selling and administrative expense cost reductions, which includes component cost reductions, reorganization of our sales and commission structure and

## MANAGEMENT'S DISCUSSION AND ANALYSIS

### FOR THE THREE MONTHS ENDED MARCH 31, 2020 AND 2019

realignment or our discount programs. On a pro forma basis approximately \$11.0 million in savings are projected for fiscal year 2020.

The Company expects considerable margin improvement in the second half of 2020 as greenhouse renovations are completed, costs are reduced and operational efficiencies improve.

#### Private Placement

In connection with the Company's Reverse Takeover, on April 2, 2019 Indus completed a private placement offering (the "Private Placement"), in which 3,436 subscription receipts ("Subscription Receipts") were issued at a price of CDN\$15.65 per Subscription Receipt for gross proceeds of approximately US\$40 million. The gross proceeds of the Private Placement, less certain associated expenses, were deposited into escrow (the "Escrowed Proceeds") pending satisfaction of certain specified release conditions (the "Escrow Release Conditions"), all of which were satisfied immediately prior to the completion of the Transaction. As a result, the Escrowed Proceeds were released to FinanceCo prior to the closing of the Transaction, and each Subscription Receipt was automatically converted, for no additional consideration, into one common share of FinanceCo. Following satisfaction of the Escrow Release Conditions, in connection with the Transaction, and the former holders thereof (including the former holders of FinanceCo Shares pursuant to a three-cornered amalgamation, and the former holders thereof (including the former holders of FinanceCo Shares acquired upon conversion of the Subscription Receipts) each received one Subordinate Voting Share in exchange for each FinanceCo share held.

#### Cash Flows

The following table presents the Company's net cash inflows and outflows from the condensed interim consolidated financial statements of the Company for the three months ended March 31, 2020 and 2019.

Three Months Ended March 31,			 Chan	ge
(in thousands)	2020	2019	\$	%
Net cash used in operating activities	\$ (2,352)	\$ (4,342)	\$ 1,990	46%
Net cash used in investing activities	(1,284)	(2,976)	1,692	57%
Net cash provided by financing activities	2,879	(258)	3,137	-1216%
Change in cash and cash equivalents and restricted cash	\$ (757)	\$ (7,576)	\$ 6,819	90%

#### Cash used in operating activities

Net cash used in operating activities was \$2,352 for the three months ended March 31, 2020, a decrease of \$2 million or 46%, compared to the three months ended March 31, 2019. The reduction was primarily driven by receivable collection activities, improved inventory turnover and higher operating payables and liabilities, partially offset by investments in biological assets.

#### Cash used in investing activities

Net cash used in investing activities was \$1,284 for the three months ended March 31, 2020, a decrease of \$1.7 million, compared to the same period in the prior year. The outflow was primarily capital additions related to the improvements

## MANAGEMENT'S DISCUSSION AND ANALYSIS

### FOR THE THREE MONTHS ENDED MARCH 31, 2020 AND 2019

to the cultivation greenhouses and facility renovation for the flower packaging line. Capital expenditures in 2019 included an investment in a strategic partner of \$1.5 million.

#### Cash provided by financing activities

Net cash provided by financing activities was \$2,879 for the three months ended March 31, 2020, compared to a net financing repayment of \$258 in the same period of the prior year. The inflow consisted primarily of \$3.3 million in net proceeds from bridge financing in the quarter, partially offset by \$501 in lease obligation payments. The bridge financing was refinanced in April 2020 with the \$16.1 million convertible debenture financing.

We expect that our cash on hand and cash flows from operations, along with proceeds from the \$15.1 million convertible debenture financing, in conjunction with the cost improvement programs described above, will be adequate to meet our capital requirements and operational needs for the next 12 months.

#### Working Capital and Cash on Hand

The following table presents the Company's cash on hand and working capital position as of March 31, 2020 and 2019.

	March 31, Decem		March 31,		ember 31,		Chan	ge
(in thousands)		2020		2019		\$	%	
Working capital	\$	9,927	\$	10,004	Ş	5 (77)	-1%	
Cash on hand	\$	587	\$	1,344	\$	5 (757)	-56%	

At March 31, 2020, we had \$587 of cash and \$9,927 of working capital, compared with \$1,344 of cash and \$10,004 of working capital at December 31, 2019. The reduction in cash was primarily due to cash used to fund operations.

The Company's working capital is expected to be significantly impacted by the convertible debenture financing, growth in operations, increased cultivation output, as well as anticipated margin improvement from decreased outsourcing of cannabis raw materials, and execution of the Company's cost-cutting measures.

#### **Contractual Obligations**

On May 14, 2019, the Company entered into a definitive agreement to acquire the assets of W The Brand ("W Vapes"), a multi-state manufacturer and distributor of cannabis concentrates, cartridges and disposable pens, in a cash and stock transaction comprised of \$10 million in cash and \$10 million in shares of Indus Holdings, Inc. subordinate voting shares based on a deemed value of CDN\$15.65 per share. The Company is working to resolve regulatory items outstanding prior to closing the transaction.

The Company and its subsidiaries, in the normal course of business, have entered into lease agreements for corporate offices, a cultivation facility, a manufacturing facility, operating assets and distribution centers. As of March 31, 2020, maturities of these lease obligations were:

## MANAGEMENT'S DISCUSSION AND ANALYSIS

### FOR THE THREE MONTHS ENDED MARCH 31, 2020 AND 2019

(in thousands)	March 31, 2020
Less than 1 year	\$ 2,83
1 - 3 years	11,33
4 - 5 Years	7,22
Greater than 5 years	22,7
Total	\$ 44,16

The Company is responsible for real estate taxes and common operating expenses incurred by the building or facility in which it leases space in addition to the future minimum rentals disclosed above.

The Company had the following additional obligations at March 31, 2020 and December 31, 2019:

Maturity	Maturity: <1 Year		Maturity: >1 Year	
March 31,	December 31,	March 31,	December 31,	
2020	2019	2020	2019	
\$ 10,006	\$ 9,060	\$ -	\$ -	
	March 31, 2020	March 31, December 31, 2020 2019	March 31, December 31, March 31, 2020 2019 2020	

#### **Off-Balance Sheet Arrangements**

As of the date of this filing, the Company does not have any material off-balance sheet arrangements that have, or are reasonably likely to have, a current or future effect on the results of the operations or financial condition of the Company, including, and without limitation, such considerations as liquidity and capital resources.

#### 4. RELATED PARTY TRANSACTIONS

Transactions with related parties are entered into in the normal course of business and are measured at the amount established and agreed to by the parties.

Indus receives certain administrative, operational and consulting services through a Management Services Agreement with Edibles Management, LLC ("EM"). EM is a limited liability company owned by the co-founders of Indus and was formed to provide Indus with certain administrative functions comprising: cultivation, distribution, and production operations support; general administration; corporate development; human resources; finance and accounting; marketing; sales; legal and compliance. The agreement provides for the dollar-for-dollar reimbursement of expenses incurred by EM in performance of its services. Amounts paid to EM for the three months ended March 31, 2020 and 2019 were \$2,840 and \$2,674, respectively.

In April 2015, Indus entered into a services agreement with Olympic Management Group ("OMG"), for advisory and technology support services, including the access and use of software licensed to OMG to perform certain data processing and enterprise resource planning (ERP) operational services. OMG is owned by one of the Company's cofounders. The agreement provides for the dollar-for-dollar reimbursement of expenses incurred by OMG in performance of its services. Amounts paid to OMG for the three months ended March 31, 2020 and 2019 were \$11 and \$40, respectively.

## MANAGEMENT'S DISCUSSION AND ANALYSIS

### FOR THE THREE MONTHS ENDED MARCH 31, 2020 AND 2019

### 5. CRITICAL ACCOUNTING ESTIMATES

The preparation of the Company's consolidated financial statements requires management to make judgments, estimates and assumptions that affect the application of policies and reported amounts of assets and liabilities, and revenue and expenses. Actual results may differ from these estimates. The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised if the revision affects only that period or in the period of the revision and future periods if the review affects both current and future periods.

Significant judgments, estimates and assumptions that have the most significant effect on the amounts recognized in the consolidated financial statements are described below.

- Estimated Useful Lives and Depreciation of Property and Equipment Depreciation of property and equipment is dependent upon estimates of useful lives which are determined through the exercise of judgment. The assessment of any impairment of these assets is dependent upon estimates of recoverable amounts that take into account factors such as economic and market conditions and the useful lives of assets.
- Estimated Useful Lives and Amortization of Intangible Assets Amortization of intangible assets is recorded on a straight-line basis over their estimated useful lives, which do not exceed the contractual period, if any.
- Fair Value of Biological Assets and Inventory In calculating the value of the biological assets and inventory, management is required to make a number of estimates, including estimating the stage of growth of the cannabis up to the point of harvest, harvesting costs, selling costs, sales price, expected yields for the cannabis plants. In calculating final inventory values, management is required to determine an estimate of spoiled or expired inventory and compare the inventory cost to estimated net realizable value.
- Fair Value of Investments in Private Entities The Company uses discounted cash flow model to determine fair value of its investment in private entities. In estimating fair value, management is required to make certain assumptions and estimates such as discount rate, long term growth rate, estimated free cash flows.
- Share-Based Compensation The Company uses the Black-Scholes option-pricing model to determine the fair
  value of stock options and warrants granted. In estimating fair value, management is required to make certain
  assumptions and estimates such as the expected life of units, volatility of the Company's future share price, risk
  free rates, future dividend yields and estimated forfeitures at the initial grant date. Changes in assumptions
  used to estimate fair value could result in materially different results.
- Deferred Tax Asset and Valuation Allowance Deferred tax assets, including those arising from tax loss carryforwards, requires management to assess the likelihood that the Company will generate sufficient taxable earnings in future periods in order to utilize recognized deferred tax assets. Assumptions about the generation of future taxable profits depend on management's estimates of future cash flows. In addition, future changes in tax laws could limit the ability of the Company to obtain tax deductions in future periods. To the extent that future cash flows and taxable income differ significantly from estimates, the ability of the Company to realize the net deferred tax assets recorded at the reporting date could be impacted.
- Business Combinations A business combination is defined as an acquisition of assets and liabilities that constitute a business. A business consists of inputs, including non-current assets and processes, including

## MANAGEMENT'S DISCUSSION AND ANALYSIS

### FOR THE THREE MONTHS ENDED MARCH 31, 2020 AND 2019

operational processes, that when applied to those inputs have the ability to create outputs that provide a return to the Company. Business combinations are accounted for using the acquisition method of accounting. The consideration of each acquisition is measured at the aggregate of the fair values of tangible and intangible assets obtained, liabilities and contingent liabilities incurred or assumed, and equity instruments issued by the Company at the date of acquisition. Key assumptions routinely utilized in allocation of purchase price to intangible assets include projected financial information such as revenue projections for companies acquired. As of the acquisition date, goodwill is measured as the excess of consideration given, generally measured at fair value, and the net of the acquisition date fair values of the identifiable assets acquired and the liabilities assumed.

 Goodwill – Goodwill represents the excess of the purchase price paid for the acquisition of an entity over the fair value of the net tangible and intangible assets acquired. Goodwill that has an indefinite useful life is not subject to amortization and is tested annually for impairment, or more frequently if events or changes in circumstances indicate that goodwill might be impaired. Any goodwill impairment loss is recognized in the consolidated statements of operations in the period in which the impairment is identified. Impairment losses on goodwill are not subsequently reversed.

#### 6. FINANCIAL INSTRUMENTS AND FINANCIAL RISK

The Company's financial instruments consist of cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities; current portion of long-term debt; and long-term debt. The carrying values of these financial instruments approximate their fair values.

Financial instruments recorded at fair value are classified using a fair value hierarchy that reflects the significance of the inputs used to make the measurements. The hierarchy is summarized as follows:

- Level 1 Quoted prices (unadjusted) that are in active markets for identical assets or liabilities
- Level 2 Inputs that are observable for the asset or liability, either directly (prices) for similar assets or liabilities in active markets or indirectly (derived from prices) for identical assets or liabilities in markets with insufficient volume or infrequent transactions
- Level 3 Inputs for assets or liabilities that are not based upon observable market data

The Company has exposure to the following risks from its use of financial instruments and other risks to which it is exposed and assess the impact and likelihood of those risks. These risks include: market, credit, liquidity, asset forfeiture, banking and interest rate risk.

#### <u>Credit Risk</u>

Credit risk is the risk of a potential loss to the Company if a customer or third party to a financial instrument fails to meet its contractual obligations. The maximum credit exposure at March 31, 2020 and December 31, 2019 is the carrying amount of cash and cash equivalents and accounts receivable. All cash and cash equivalents are placed with U.S. financial institutions.

## MANAGEMENT'S DISCUSSION AND ANALYSIS

### FOR THE THREE MONTHS ENDED MARCH 31, 2020 AND 2019

The Company provides credit to its customers in the normal course of business and has established credit evaluation and monitoring processes to mitigate credit risk but has limited risk as a significant portion of its sales are transacted with cash.

#### Liquidity Risk

Liquidity risk is the risk that the Company will not be able to meet its financial obligations associated with financial liabilities. The Company manages liquidity risk through the management of its capital structure. The Company's approach to managing liquidity is to ensure that it will have sufficient liquidity to settle obligations and liabilities when due.

#### Market Risk

Strategic and operational risks arise if the Company fails to carry out business operations and/or to raise sufficient equity and/or debt financing. These strategic opportunities or threats arise from a range of factors that might include changing economic and political circumstances and regulatory approvals and competitor actions. The risk is mitigated by consideration of other potential development opportunities and challenges which management may undertake.

#### Interest Rate Risk

Interest rate risk is the risk that the fair value or the future cash flows of a financial instrument will fluctuate as a result of changes in market interest rates. The Company's interest-bearing loans and borrowings are all at fixed interest rates; therefore, the Company is not exposed to interest rate risk on these financial liabilities. The Company considers interest rate risk to be immaterial.

#### Price Risk

Price risk is the risk of variability in fair value due to movements in equity or market prices. Cannabis is a developing market and likely subject to volatile and possibly declining prices year over year as a result of increased competition. Because adult-use cannabis is a newly commercialized and regulated industry in the state of California, historical price data is either not available or not predictive of future price levels. There may be downward pressure on the average price for cannabis. There can be no assurance that price volatility will be favorable to Indus or in line with expectations. Pricing will depend on general factors including, but not limited to, the number of licenses granted by the state and local governments, the supply such licensees are able to generate and consumer demand for cannabis. An adverse change in cannabis prices, or in investors' beliefs about trends in those prices, could have a material adverse outcome on the Company and its valuation.

#### Asset forfeiture risk

Because the cannabis industry remains illegal under U.S. federal law, any property owned by participants in the cannabis industry which are either used in the course of conducting such business, or are the proceeds of such business, could be subject to seizure by law enforcement and subsequent civil asset forfeiture. Even if the owner of the property were never charged with a crime, the property in question could still be seized and subject to an administrative proceeding by which, with minimal due process, it could be subject to forfeiture.

# INDUS HOLDINGS, INC. AND AFFILIATES MANAGEMENT'S DISCUSSION AND ANALYSIS

## FOR THE THREE MONTHS ENDED MARCH 31, 2020 AND 2019

#### **Banking risk**

Notwithstanding that a majority of states have legalized medical and/or adult-use marijuana, there has been no change in U.S. federal banking laws related to the deposit and holding of funds derived from activities related to the marijuana industry. Given that U.S. federal law provides that the production and possession of cannabis is illegal, there is a strong argument that banks cannot accept for deposit funds from businesses involved with the cannabis industry. Consequently, businesses involved in the cannabis industry often have difficulty accessing the U.S. banking system and traditional financing sources. The inability to open bank accounts with certain institutions may make it difficult to operate the businesses of the Company and its subsidiaries and leaves their cash holdings vulnerable.

#### 7. RISK FACTORS

Risk factors describing the major risks to our business can be found under Section 17 in our Listing Statement filed on April 29, 2019 under the Company's profile on SEDAR. There have been no material changes in our risk factors from those previously discussed in our Listing Statement.

#### 8. OUTSTANDING SHARE DATA

	Number of Shares
(in thousands)	(on an as converted basis)
Issued and Outstanding	
Subordinate voting shares	33,342
Super voting shares	203
Reserved for Issuance	
Options	4,633
Restricted Stock Units	663
Warrants	2,769
Convertible debenture shares	80,379
Convertible debenture warrants	80,379

As of May 28, 2020, the Company had the following securities issued and outstanding:

#### 9. SUBSEQUENT EVENTS

The Company has evaluated subsequent events through May 28, 2020, the date the financial statements were available to be issued.

#### Financing

On April 13, 2020, the Company announced that its subsidiary, Indus Holding Company, entered into a \$15.1 million senior secured convertible debenture and warrant purchase agreement. In May 2020 an additional \$1 million was funded to bring the total convertible debenture amount to \$16.1 million. The convertible debentures are convertible, at a conversion price of \$0.20 per share, into an aggregate of 80.4 million subordinate voting shares of the Company, and the Company issued warrants to purchase an aggregate of 80.4 million subordinate voting shares at an exercise price of \$.28 per share. The financing yielded the Company approximately \$11.5 million after repayment of \$3.8 million

## MANAGEMENT'S DISCUSSION AND ANALYSIS

### FOR THE THREE MONTHS ENDED MARCH 31, 2020 AND 2019

in bridge financing received during the first quarter, plus accrued interest thereon, and transaction related expenses of approximately \$600. The debentures bear interest at 5.5% per annum and will mature in October 2023, and the warrants also mature in October 2023.